glp 1 and substance use disorder GLP-1 receptor agonists disorders: new large-scale evidence from the BMJ A cohort study published in the BMJ this week (Cai, Choi, Xie, Al-Aly, 2026) examined over 600,000 US veterans Can GLP-1 medications impact substance

Investigational uses in heart failure, NASH, and neurodegeneration are currently being explored, often leveraging multi-receptor agonist platforms that combine GLP-1, GIP, and glucagon receptor activation

A long road is ahead of us to better understand the complexity of HFpEF, but a comprehensive multimarker approach may be recommended to characterise specific HFpEF phenotypes/endotypes for optimising therapy and to stratify risk

AOD-9604 is a modified 16-amino acid fragment of human growth hormone (hGH), corresponding to the C-terminal region (amino acids 176191) with an added tyrosine residue at position 177

Solicite um diagnstico gratuito de TI

Zhou, Z.D., et al., Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges

Wang Z, Franke K, Bal G, Li Z, Zuberbier T, Babina M